CNCR Profile
The Loncar Cancer Immunotherapy ETF aims to replicate the performance of an index consisting of around 30 pharmaceutical and biotechnology companies that are prominently focused on developing innovative immunotherapies for cancer treatment. This index is carefully curated by the fund's index provider to include firms with a significant commitment to leveraging the body's immune system to combat various forms of cancer. The selection criteria emphasize the strategic importance of immunotherapy research and development within each company's portfolio.d.
The ETF is designed to invest primarily in the common stock of these selected companies, as well as American Depositary Receipts (ADRs) representing foreign firms that are part of the index. The fund endeavors to allocate a substantial majority of its assetsâ€at least 80%â€in line with the index's component securities. This focus ensures that the ETF closely mirrors the performance of the index and maintains a concentrated exposure to the cancer immunotherapy sector.
As an actively managed fund, the Loncar Cancer Immunotherapy ETF leverages a concentrated investment strategy, with an emphasis on high-impact firms that are at the forefront of immunotherapy innovation. This approach allows the fund to align closely with the underlying index and capture the growth potential of companies dedicated to advancing cancer treatments through immune system modulation. The non-diversified nature of the fund means that its investments are highly concentrated in this specific therapeutic area, reflecting a strategic focus on companies with substantial contributions to cancer immunotherapy.
The ETF's concentrated approach and adherence to index components allow it to deliver targeted exposure to the rapidly evolving field of cancer immunotherapy. By focusing on firms with high strategic investment in this niche, the fund aims to offer investors a precise avenue to capitalize on advancements in cancer treatment, while also bearing the inherent risks associated with a specialized investment strategy. The ongoing management and investment decisions are directed towards maintaining alignment with the index and optimizing returns based on developments within the immunotherapy sector.
|
